Discussions with leaders: Arie Belldegrun, MD, looks at his career and current endeavors as a physician and international medical entrepreneur.
Page 1821
Time-varying models for PET: Morris and colleagues review the history and development of modeling of brain PET data acquired during “nonsteady” states, i.e., when brain conditions change during imaging.
Page 1824
Evolving practice in melanoma: Dougherty and colleagues provide an educational overview of guidelines for baseline imaging in newly diagnosed melanoma, FDA-approved checkpoint inhibitors for advanced melanoma treatment, and optimal use of PET/CT in surveillance of treated disease.
Page 1838
Dosimetry in clinical practice: Bardiès and colleagues make a case for the role of patient dosimetry in molecular radiotherapy to optimize and personalize treatments, meet regulatory requirements on radiation protection, and develop supporting data to improve management.
Page 1846
Outpatient 177Lu-PSMA treatment: Zagni and colleagues offer commentary on the feasibility of 177Lu-PSMA administration as an outpatient procedure for prostate cancer, analyzing safety aspects, advantages, and disadvantages.
Page 1848
Italy and outpatient RPT: Holzwarth supplements JNM commentary by Zagni and colleagues with information on Italian legislation allowing outpatient radiopharmaceutical treatment with 177Lu-PSMA at the discretion of the physician and local medical physics and radiation protection experts.
Page 1850
Challenges with PSMA RPT: Jadvar and colleagues review clinical challenges evident since FDA and European approval of PSMA-targeted radiopharmaceutical therapy and suggest criteria that might be fine-tuned to increase the likelihood of favorable response in specific patients.
Page 1851
PET/MRI in breast cancer: Jannusch and colleagues investigate whether 18F-FDG PET/MRI in addition to conventional staging leads to changes in therapeutic management of newly diagnosed breast cancer and assess relative diagnostic accuracy in disease staging.
Page 1855
18F-FTT kinetics in breast cancer: Young and colleagues characterize the pharmacokinetics of the PARP-inhibitor 18F-fluorthanatrace in breast cancer, assess optimal image timing for clinical trials, and correlate tracer uptake with matched surgical specimens.
Page 1862
Systemic immunity and [18F]F-AraG PET: Levi and colleagues research the utility of [18F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status before starting immunotherapy in non–small cell lung cancer.
Page 1869
Metabolic risk scores in DLBCL: Vergote and colleagues explore the prognostic value of 4 novel metabolic risk scores in a real-life cohort of diffuse large B-cell lymphoma patients and compare results with the revised International Prognostic Index.
Page 1876
[68Ga]Ga-NYM046 PET/CT: Lou and colleagues investigate the diagnostic efficacy of [68Ga]Ga-NYM046 PET/CT in animal models and in patients with clear cell renal cell carcinoma and compare its performance with that of 18F-FDG PET/CT.
Page 1884
CD70-targeted immuno-PET/CT for ccRCC: Zhou and colleagues describe the potential of cluster of differentiation 70–targeted immuno-PET/CT imaging as a precise and superior method for evaluating tumor burden and suspected metastases in patients with clear cell renal carcinoma.
Page 1891
[18F]FDG and [68Ga]Ga-FAPI-04 PET/CT: Michalski and colleagues report on the prognostic value of PET-based biomarkers on [18F]FDG and [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in patients with aggressive neuroendocrine neoplasms and correlate resulting uptake differences and progression-free survival.
Page 1899
Trop2 immuno-PET/CT in lung cancers: Huang and colleagues detail development and translation of novel trophoblast cell surface antigen 2 single-domain antibody tracers for differentiation of lung inflammation from cancer.
Page 1904
Intraarterial PRRT in meningioma: Amerein and colleagues analyze the safety and efficacy of intraarterial peptide receptor radionuclide therapy in patients with advanced, progressive meningiomas.
Page 1911
213Bi-FAPI-46 therapy: Helisch and colleagues provide initial clinical experience with feasibility, tolerability, and response of fractionated 213Bi–fibroblast activation protein inhibitor–46 treatment in patients with progressive metastatic solid tumors.
Page 1917
PET and mpMRI PCa detection: Sonni and colleagues describe clinically significant prostate cancers evaluated with PSMA PET/CT and multiparametric MRI, focusing on tumors detected solely by PET/CT and overlooked by mpMRI.
Page 1923
[177Lu]Lu-PSMA-617 outcomes: Muniz and colleagues use real-world clinical data to examine prostate-specific antigen response and overall survival after [177Lu]Lu-PSMA-617 therapy in patients with liver metastases from castration-resistant prostate cancer.
1932
Response assessment on early [177Lu]Lu-PSMA SPECT: Swiha and colleagues investigate 4-h imaging as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation of treatment response in men with metastatic castration-resistant prostate cancer.
Page 1939
177Lu-PSMA-617 SPECT/CT in mCRPC: Demirci and colleagues analyze the roles of total tumor volumes and new lesions determined by LuPSMA SPECT/CT in early treatment cycles to predict subsequent outcomes in metastatic castration-resistant prostate cancer.
Page 1945
FAP and PSMA in CRPC: Huang and colleagues evaluate fibroblast activation protein expression in a range of castration-resistant prostate cancer tumors and compare these results with prostate-specific membrane antigen expression.
Page 1952
Exendin PET and insulinoma localization: Boss and colleagues compare the diagnostic accuracy of 68Ga-NODAGA-exendin-4 PET/CT with that of routine imaging procedures for localization of insulinomas in patients with endogenous hyperinsulinemic hypoglycemia.
Page 1959
MIRDcell V4: Katugampola and colleagues present artificial intelligence tools in a new version of their software platform that optimizes a cocktail of radiopharmaceuticals by minimizing the total disintegrations needed to achieve a specific surviving fraction of tumor cells.
Page 1965
uMI Panorama GS performance: Zhang and colleagues detail performance assessment of this new long-axial-field-of-view PET system on the basis of National Electrical Manufacturers Association NU 2-2018 and European Association of Nuclear Medicine Research Limited standards.
Page 1974
CT enhancement of nasal leech: Meng and He share a case study of a patient who, after thrombectomy, was discovered to have had a contrast-enhancing leech in the left nostril.
Page 1983
- © 2024 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.